Pharma: Page
-
Getty Images
Roivant spinoff tackles growing complexity of clinical trials
As precision medicine booms, all trials are starting to look like rare disease trials, the company said.
By Kelly Bilodeau • April 18, 2024 -
Sean Gallup via Getty Images
3 patent expirations in 2024 and how companies are pivoting
As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.
By Amy Baxter • April 17, 2024 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Chris McGrath via Getty Images
Deep DiveUkraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
New clinical trial starts are picking back up, but are still far below their bustling pre-war level.
By Meagan Parrish • April 16, 2024 -
Getty Images
Where the GLP-1 weight loss market goes will depend on data
As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.
By Amy Baxter • April 15, 2024 -
Getty Images
3 big recent trial flops
How these clinical setbacks impacted the companies, industry and patients.
By Meagan Parrish • April 12, 2024 -
Permission granted by eClinical Solutions
Q&AHow pharma’s surging M&A is impacting the industry’s tech sector
As dealmaking in biopharma picks up, the CEO of eClinical Solutions sees an opportunity for clinical software companies to make acquisitions easier to close.
By Michael Gibney • April 11, 2024 -
Permission granted by Bristol Myers Squibb
Deep DivePsychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
By Jacob Bell • April 10, 2024 -
Getty Images
Biotech SpotlightWhat’s old is new: The revival of a one-time radiotherapy cancer treatment
TAE Life Sciences is bringing radiation-based cancer therapy to clinical trials globally in the coming years.
By Amy Baxter • April 10, 2024 -
Getty Images
Cutting pills. Rationing insulin. How Americans struggle to pay for drugs.
More than 20% of Americans are forgoing prescription medications due to costs, according to a recent survey.
By Amy Baxter • April 9, 2024 -
Getty Images
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
Biosimilars promise market competition for branded biologics, which in theory could drive down prices. But so far, winning market share has been a struggle.
By Michael Gibney • April 9, 2024 -
Getty Images
Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced?
The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?
By Alexandra Pecci • April 8, 2024 -
Getty Images
Women want to participate in clinical trials. Lack of flexibility is still a problem.
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line, but even small changes can fuel participation.
By Kelly Bilodeau • April 8, 2024 -
Permission granted by Avenga
Sponsored by AvengaUnlocking growth: How GenAI can help pharma companies convert new clients
GenAI is profoundly reshaping various facets of the pharmaceutical industry. Projections indicate that the global GenAI market in pharma will soar to $2258.1 million by 2032.
By Olena Domanska, Data Science Engineering Manager at Avenga • April 8, 2024 -
Getty Images
Viral return: 3 U.S. cases concerning experts
Infectious diseases that were “off the playing field” are now making a comeback.
By Meagan Parrish • April 5, 2024 -
Getty Images
As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
By Amy Baxter • April 3, 2024 -
Getty Images
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
By Michael Gibney • April 2, 2024 -
Scott Olson/Staff via Getty Images
With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care
Eledon Pharmaceuticals is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
By Kelly Bilodeau • April 1, 2024 -
Permission granted by EMD Serono
Q&ATo advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.
By Alexandra Pecci • April 1, 2024 -
Permission granted by Rivus Pharmaceuticals
To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach
Rivus’ controlled metabolic accelerators are an emerging new potential competitor to popular weight loss and diabetes drugs from Novo Nordisk and Eli Lilly.
By Amy Baxter • March 29, 2024 -
Getty Images
Takeda plots ‘unprecedented patient diversity’ for psoriasis drug that could compete with BMS
Ahead of more guidance from the FDA on diversity in clinical trials, Takeda is aiming to beat industry standards.
By Amy Baxter • March 27, 2024 -
Permission granted by Alnylam
Alnylam turns to genealogy to find rare disease patients through family trees
A vastly underdiagnosed rare disease presents a challenge to Alnylam’s commercial team, but a family health road trip has patients talking about their hereditary risk.
By Michael Gibney • March 26, 2024 -
Permission granted by Boehringer Ingelheim
Q&AWhy a pharmacist was tapped to spearhead ‘patient excellence’ at Boehringer Ingelheim
Deborah Reardon is leading a new pillar that asks, “Are we looking at this from a patient lens and not from a Boehringer lens?”
By Alexandra Pecci • March 25, 2024 -
Getty Images
Who’s getting left behind in the weight loss bonanza?
As the new weight loss drugs take the world by storm, companies in other areas are battening the hatches for when slimmer patients need fewer medical interventions.
By Kelly Bilodeau • March 25, 2024 -
Permission granted by Gates MRI
ProfileThe pharma ‘fixer’ now helping Gates MRI’s tuberculosis battle
After getting her start as a nurse, Debra Weiss worked her way up the corporate ladder and is now COO of Gates MRI, which just launched its first phase 3 trial for tuberculosis.
By Alexandra Pecci • March 22, 2024 -
Permission granted by Wyss Institute
Q&AAn ocean of answers in a single cell — how proteomics can lead to better drugs
New tools that allow researchers to separate single cells can help map the complex web of proteins that lead to disease, providing new targets for biopharma.
By Michael Gibney • March 21, 2024
Previous
